ENTA

SEC source: 0001062993-21-012213 · form4.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,902

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.

SEC source: 0001062993-21-012201 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,161

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.

SEC source: 0001062993-21-012199 · form4.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,002

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.

SEC source: 0001062993-21-012197 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 700,728

F1 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 20, 2020.

SEC source: 0001062993-21-011498 · form4.xml · derivative · entry 2

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,800

Underlying: Common Stock · 107,800 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011498 · form4.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 702,672

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001062993-21-011518 · form4.xml · derivative · entry 2

Luu Brendan · CIK 0001842369 · Sr. VP, Business Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011518 · form4.xml · nonDerivative · entry 1

Luu Brendan · CIK 0001842369 · Sr. VP, Business Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,800

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001062993-21-011516 · form4.xml · derivative · entry 2

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011516 · form4.xml · nonDerivative · entry 1

Kieffer Tara Lynn · CIK 0001834835 · Sr. VP, New Product Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,800

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001062993-21-011512 · form4.xml · derivative · entry 3

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F3 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011512 · form4.xml · nonDerivative · entry 1

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,783

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001062993-21-011509 · form4.xml · derivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011509 · form4.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,744

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001062993-21-011504 · form4.xml · derivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F2 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011504 · form4.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,718

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

SEC source: 0001062993-21-011500 · form4.xml · derivative · entry 2

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,400

Underlying: Common Stock · 28,400 shares

Expires 2031-11-19

F3 · derivative.exercise_date: Such option will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021).

SEC source: 0001062993-21-011500 · form4.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,559

F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs vest in equal annual installments over four years from the date of grant (November 19, 2021). The restricted stock unit shares that vest will be issued on the first December 1 after the applicable vesting date, subject to withholding of a portion of the vested shares to satisfy tax withholding requirements.

F2 · balance_after: The amount of securities beneficially owned by the reporting person was incorrectly stated on the Form 4 filed on January 8, 2021 as "61,759" instead of "49,759." The amount of securities beneficially owned, as reported in column 5 of this Form 4, corrects this error.

SEC source: 0001177648-21-000029 · edgar.xml · derivative · entry 5

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,953

Underlying: Common Stock · 9,547 shares

Expires 2027-11-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option, representing a right to purchase a total of 23,500 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017).

SEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,944

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

SEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,044

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.74 to $85.63, inclusive.

SEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,539

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.74 to $84.73, inclusive.

SEC source: 0001177648-21-000029 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000027 · edgar.xml · derivative · entry 6

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,770

Underlying: Common Stock · 4,047 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 4

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,944

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive.

SEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000027 · edgar.xml · derivative · entry 5

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,817

Underlying: Common Stock · 13,453 shares

Expires 2025-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,944

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive.

SEC source: 0001177648-21-000027 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,397

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000025 · edgar.xml · nonDerivative · entry 1

Luly Jay R. · CIK 0001571211 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 676,972

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2020.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.23, inclusive.

SEC source: 0001177648-21-000023 · edgar.xml · derivative · entry 1

Hata Yujiro S · CIK 0001649119 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,144

Underlying: Common Stock · 13,144 shares

Expires 2031-08-19

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over three years, beginning from the date of grant (August 19, 2021).

SEC source: 0001177648-21-000019 · edgar.xml · derivative · entry 1

Vance Terry · CIK 0001572282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-03-02

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders.

SEC source: 0001177648-21-000017 · edgar.xml · derivative · entry 1

Russell Lesley · CIK 0001374636 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-03-02

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders.

SEC source: 0001177648-21-000015 · edgar.xml · derivative · entry 1

Peterson Kristine · CIK 0001508596 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-03-02

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders.

SEC source: 0001177648-21-000011 · edgar.xml · derivative · entry 1

CARTER BRUCE L A · CIK 0001225503 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-03-02

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders.

SEC source: 0001177648-21-000013 · edgar.xml · derivative · entry 1

FOLETTA MARK G · CIK 0001236389 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-03-02

F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders.

SEC source: 0001177648-21-000008 · edgar.xml · derivative · entry 6

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,872 shares

Expires 2022-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000008 · edgar.xml · derivative · entry 5

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,672 shares

Expires 2022-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000008 · edgar.xml · derivative · entry 4

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,149 shares

Expires 2022-12-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable.

SEC source: 0001177648-21-000008 · edgar.xml · nonDerivative · entry 3

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,918

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000008 · edgar.xml · nonDerivative · entry 2

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,046

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000008 · edgar.xml · nonDerivative · entry 1

Or Yat Sun · CIK 0001571212 · Sr. VP & CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001177648-21-000006 · edgar.xml · derivative · entry 1

Luu Brendan · CIK 0001842369 · Sr. VP, Business Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: Twenty-five percent (25%) of such option will become exercisable on January 25, 2022 (the "Anniversary Date"), with the remainder to become exercisable quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over three years from the Anniversary Date (in each case subject to the optionholder's continued employment).

SEC source: 0001177648-21-000002 · edgar.xml · nonDerivative · entry 1

MELLETT PAUL J · CIK 0001185034 · Treasurer and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,759

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2020.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.865, inclusive.

SEC source: 0001177648-20-000059 · edgar.xml · derivative · entry 4

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

F5 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020.

F5 · derivative.expiration_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020.

SEC source: 0001177648-20-000059 · edgar.xml · nonDerivative · entry 2

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,248

F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award.

SEC source: 0001177648-20-000059 · edgar.xml · nonDerivative · entry 1

Gardiner Nathaniel S. · CIK 0001607643 · Sr. VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,788

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020. The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020.

F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

SEC source: 0001177648-20-000055 · edgar.xml · derivative · entry 3

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Restricted stock units convert into ENTA common stock on a one-for-one basis.

F4 · derivative.exercise_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020.

F4 · derivative.expiration_date: On November 18, 2016, the reporting person was granted 10,500 restricted stock units. 5,250 restricted stock units have previously vested and the remainder vested on November 18, 2020.

SEC source: 0001177648-20-000055 · edgar.xml · nonDerivative · entry 2

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,944

F3 · shares: Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of the restricted stock unit award.

SEC source: 0001177648-20-000055 · edgar.xml · nonDerivative · entry 1

Adda Nathalie · CIK 0001646976 · Sr. VP & Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,484

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of ENTA common stock subject to a restricted stock unit award granted on November 18, 2016 that vested on November 18, 2020. The settlement and issuance of the shares was subject to continued employment and occurred on December 15, 2020.

F2 · price: Restricted stock units convert into ENTA common stock on a one-for-one basis.